Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Recent Advances in Biomaterial Designs for Assisting CAR-T Cell Therapy Towards Potential Solid Tumor Treatment

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Bright future or blind alley? CAR-T cell therapy for solid tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Extant challenges and optimization strategies for CAR-T cell therapy for solid tumors

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Recent Advancements in Biomaterials for CAR-T Immunotherapy

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors.

Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

CAR-T in solid tumors: Blazing a new trail through the brambles

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy